Overview

Setrusumab vs Bisphosphonates in Subjects 2 to <5 Years of Age With Osteogenesis Imperfecta

Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the effect of setrusumab vs intravenous bisphosphonates (IV-BP) on reduction in fracture rate, including morphometric vertebral fractures in pediatric participants.
Phase:
Phase 3
Details
Lead Sponsor:
Ultragenyx Pharmaceutical Inc
Treatments:
Diphosphonates